NCT04630080 is a NA clinical trial of Scalp cooling in Breast Cancer, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT04630080?

NCT04630080 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT04630080?

Interventions in NCT04630080: Scalp cooling.

What condition does NCT04630080 study?

NCT04630080 studies Breast Cancer.

Is NCT04630080 still recruiting?

NCT04630080 is currently active, enrolled. Last updated 9 January 2026.

Last reviewed 2026-01-09 · How we verify

NCT04630080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alopecia Prevention Scalp Cooling in Chinese Breast Cancer Patients

Active, enrolled NA Last updated 9 January 2026

What this trial tests

NA trial testing Scalp cooling in Breast Cancer in 25 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 January 2021

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	25
Start date	8 January 2021
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across Hong Kong

Drugs / interventions tested

Scalp cooling

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 18 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Orbis Paxman Hair Loss Prevention System is a new equipment introduced to Hong Kong in 2017. Although this device has been widely used in the United States, Europe and Australia, acceptability, efficacy and safety data in Chinese have not yet been available. The objective of this prospective study is to collect clinical data in Chinese patients using the Orbis Paxman Hair Loss Prevention System to prevent chemotherapy-induced alopecia. This project seeks to demonstrate that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?
Wikramanayake TC, Haberland NI, Akhundlu A, Laboy Nieves A, et al · · 2023 · cited 37× · PMID 37185388 · DOI 10.3390/curroncol30040275

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04630080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 9 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing